$VRAX Balance Sheet | Understand Stock

$VRAX

$1.15 -$0.04 (3.36%) After hours

Financial Statements

In millions of USD, except per-share amounts

	Q4 FY2026 As of Mar 31, 2026	Q4 FY2025 As of Mar 31, 2025	Q4 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Mar 31, 2022
Assets
Current assets:
Cash
VAT receivable
Inventories
Prepaid expenses and deposits
Total current assets
Non-current assets
Right-of-use assets, net
Property, plant & equipment, net
Intangible software, net
Total non-current assets

Total assets
Liabilities
Current liabilities:
Accounts payable and accrued liabilities
Lease liabilities, current
Accounts payable - related parties
Loan payable
Deferred revenue
Due to shareholder
Total current liabilities

Non-current liabilities:
Non-current lease liabilities
Total liabilities
Virax Biolabs Shareholders' equity
Ordinary shares, $0.01 par value, 2,000,000 shares authorized; 579,218 and 173,679 issued and outstanding as of March 31, 2026 and 2025, respectively
Class A
Class B
Total ordinary shares, $0.01 par value, 2,000,000 shares authorized; 579,218 and 173,679 issued and outstanding as of March 31, 2026 and 2025, respectively

Reserves
Accumulated deficit
Accumulated Other Comprehensive Income (loss)
Total shareholders' equity (Virax Biolabs)
Non-controlling interests
Total shareholders' equity attributable to Virax Biolabs ordinary shareholders
Total liabilities and shareholders' equity

Comments